Shield Therapeutics PLC - Gateshead Quays, England-based commercial stage pharmaceutical company focused on the commercialisation of its oral therapy for iron deficiency - Sees strong prescription growth in the second quarter and first half of 2023. Total prescriptions for second quarter increase 50% to 15,800 compared to the first quarter. In first half of 2023, total prescriptions grow to around 26,300 which exceeds total prescription volumes for all of 2022. The company says that this growth in the first half means Shield is likely to meet its 2023 goal for US Accrufer prescriptions.
Accrufer is a pharmaceutical product that is designed to address a significant unmet need for patients suffering from iron deficiency.
Chief Executive Officer Greg Madison says: "Looking ahead, the growth in Accrufer prescriptions seen in the second quarter provides further reason for optimism in the second half of the year, as the still relatively new teams hit full stride. We continue to believe there is a very substantial market opportunity for Accrufer"
Current stock price: 8.00 pence, up 14%
12-month change: up 43%
By Will Neill, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved
Shield Thera (STX)